CS-2803;LY2119620;LY2119620, 10 mM in DMSO;Muscarinic acetylcholine receptor,Inhibitor,inhibit,mAChR,LY-2119620,LY 2119620,LY2119620;3-aMino-5-chloro-N-cyclopropyl-4-Methyl-6-(2-(4-Methylpiperazin-1-yl)-2-oxoethoxy)thieno[2,3-b]pyridine-2-carboxaMide;3-amino-5-chloro-N-cyclopropyl-4-methyl-6-[2-(4-methyl-1-piperazinyl)-2-oxoethoxy]-thieno[2,3-b]pyridine-2-carboxamide;Thieno[2,3-b]pyridine-2-carboxamide,3-amino-5-chloro-N-cyclopropyl-4-methyl-6-[2-(4-methyl-1-piperazinyl)-2-oxoethoxy]-;3-aMino-5-chloro-N-cyclopropyl-4-Methyl-6-(2-(4-Methylpiperazin-1-yl)-2-oxoethoxy)thieno[2,3-b]pyridine-2-carboxaMide USP/EP/BP
LY2119620 is a positive allosteric modulator of the M2 and M4 muscarinic acetylcholine receptors (mAChRs). It binds to allosteric sites on M2 and M4 receptors with KB values ranging from 1.8 to 3.4 μM. LY2119620 potentiates the activity of the AChR agonist acetylcholine (ACh; ) and the mAChR agonists iperoxo and oxotremorine M at human recombinant M2 and M4 receptors expressed in CHO cell membranes. LY2119620 also exhibits allosteric agonism at M2 and M4 receptors (23.2 and 16.8%, respectively, of the maximal ACh response).
??
LY 2119620 acts as a novel positive allosteric modulator in the treatment of schizophrenia acting as an anti-psychotic agent.
